论文部分内容阅读
目的探讨同步放化疗与树突状细胞-细胞因子活化杀伤细胞(DC-CIK)生物治疗在中晚期非小细胞肺癌(NSCLC)患者中的临床效果。方法 86例中晚期NSCLC患者随机分为观察组与对照组,每组43例,观察组给予DC-CIK与同步放化疗治疗,对照组给予单纯同步放化疗治疗,对比两组患者的临床疗效。结果观察组患者治疗有效率(RR)为90.7%(39/43),对照组为81.4%(35/43),差异有统计学意义(P>0.05)。观察组患者治疗后CD3~+、CD4~+/CD8~+、自然杀伤细胞(NK)水平均显著高于治疗前(P<0.01),对照组均显著低于治疗前(P<0.01)。观察组患者治疗后的CD3~+、CD4~+/CD8~+、NK水平显著高于对照组(P<0.01);观察组患者发热发生率显著高于对照组(P<0.01),粒细胞减少、放射性肺炎发生率显著低于对照组(P<0.05),两组患者胃肠道反应以及放射性食管炎发生率的差异无统计学意义(P>0.05)。结论 DC-CIK与同步放化疗联合用于中晚期NSCLC患者的治疗,可在获得与同步放化疗相同的近期疗效基础上,有效提高机体的抗肿瘤能力,减少粒细胞减少及放射性损伤等不良反应,值得临床推广。
Objective To investigate the clinical effect of concurrent chemoradiotherapy and dendritic cell-activated cytokine-activated killer (DC-CIK) biotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods 86 cases of advanced non-small cell lung cancer (NSCLC) were randomly divided into observation group and control group, 43 cases in each group. The observation group received DC-CIK and concurrent chemoradiotherapy and chemotherapy. The control group received simple concurrent chemoradiotherapy. The clinical efficacy was compared between the two groups. Results The response rate (RR) of the observation group was 90.7% (39/43) and that of the control group was 81.4% (35/43), the difference was statistically significant (P> 0.05). The levels of CD3 ~ +, CD4 ~ + / CD8 ~ + and NK cells in observation group were significantly higher than those before treatment (P <0.01), and were significantly lower in the control group than before treatment (P <0.01). The levels of CD3 ~ +, CD4 ~ + / CD8 ~ + and NK in observation group were significantly higher than those in control group (P <0.01). The incidence of fever in observation group was significantly higher than that in control group (P <0.01) Reduce the incidence of radiation pneumonitis was significantly lower than the control group (P <0.05), the two groups of patients with gastrointestinal reactions and the incidence of radiation esophagitis no significant difference (P> 0.05). Conclusions DC-CIK and concurrent chemoradiotherapy combined with concurrent chemotherapy for patients with advanced NSCLC can achieve the same immediate curative effect as concurrent chemoradiotherapy and effectively improve the anti-tumor ability of the body and reduce adverse reactions such as neutropenia and radiation injury , It is worth clinical promotion.